NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
Office of Special Counsel Affirms whistleblower protection for ALL gov employees
Good news! The Associated Press reports that the U.S. Merit Systems Proteciton Board ruled in favor of extending whistleblower protection to ALL government doctors, including those hired under Title 42.
Grassley Pushes FDA: Transparency, Accountability & Independence / Whistleblowers are essential Witnesses
Grassley Pushes FDA: Transparency, Accountability & Independence / Whistleblowers are essential Witnesses Wed, 8 Jun 2005 The FDA has once again demonstrated bad faith when it appointed an industry biased panel to monitor drug safety. The Washington Post reports that FDA safety officer Dr. David Graham, who blew the whistle…
Guidant Case May Involve Crime Inquiry
Guidant Case May Involve Crime Inquiry Thu, 29 Sep 2005 The New York Times reports that “criminal investigators at the Food and Drug Administration have apparently become involved in the agency’s inquiry into how the Guidant Corporation handled problems with its heart devices, said two people contacted by the investigators."…
Pfizer Statements RE: Bextra, Celebrex, Neurontin Shown to be Lies
Pfizer Statements RE: Bextra, Celebrex, Neurontin Shown to be Lies Fri, 08 Apr 2005 The New York Times reports that “as recently as Tuesday [Pfizer] assured Wall Street that sales of Celebrex and Bextra would soon rebound. It was the latest in a string of announcements by the company regarding…
Lies & Broken Promises – Drug firm Websites Fail to Disclose Test Data
Lies & Broken Promises_Drug firm Websites Fail to Disclose Test Data Sun, 9 Jan 2005 One year after PhRMA’s publicized proclamation of its “commitment to transparency” The Boston Globe reviewed pharmaceutical company websites searching for disclosure of clinical trial data. The Globe found that this voluntary approach failed miserably: “Last…
- Concealed Data | Conflict of Interest | Corrupt Practices | Current Controversies | Investigations | Miscellaneous
FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post
FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post Thu, 18 Nov 2004 The Washington Post examines FDA’s record of surveillance and the evidence is clear: since 1992 when Congress required drug companies to pay users fees to the FDA, the agency’s focus changed from safety…